The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients

Diabetes Res Clin Pract. 2008 Jul;81(1):56-60. doi: 10.1016/j.diabres.2008.02.006. Epub 2008 Mar 21.

Abstract

The aim of the study was to evaluate the effect of metformin on markers of endothelial function, vascular inflammation and factors of thrombosis in obese type 2 diabetic patients. Twenty-four type 2 diabetic patients (15 female, 9 male) previously under medical nutrition treatment (MNT)+regular exercise programme (REP) without chronic micro or macrovascular complications with the mean age of 50.5+/-1.5 years, diabetes duration of 17.9+/-6.3 months and body mass index (BMI) of 31.7+/-0.8 kg/m(2) were enrolled in the study. In the first 4 weeks, all the patients continued MNT+REP. In the following 12 weeks, metformin (mean daily dosage of 1381+/-85 mg) was added. After the first period with MNT+REP, BMI, waist circumference, fat percentage, blood pressure and HDL cholesterol decreased significantly. After metformin addition, there was a significant decrement in BMI, waist circumference, fat percentage, fasting and postprandial plasma glucose, hemoglobin A1C, plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor (VEGF) and increment in beta cell reserve values of the patients. Our results indicated that, metformin addition had beneficial effect on VEGF and PAI-1 levels in obese type 2 diabetic patients under MNT+REP, independent from its' favourable effects on BMI and glycemic control.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Blood Glucose / metabolism
  • Body Mass Index
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Exercise
  • Female
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Lipids / blood
  • Male
  • Matrix Metalloproteinase 9 / blood
  • Metformin / therapeutic use*
  • Middle Aged
  • Obesity / blood*
  • Obesity / complications
  • Obesity / physiopathology
  • Plasminogen Activator Inhibitor 1 / blood*
  • Prospective Studies
  • Vascular Endothelial Growth Factor A / blood*
  • Waist-Hip Ratio

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Lipids
  • Plasminogen Activator Inhibitor 1
  • Vascular Endothelial Growth Factor A
  • Metformin
  • Matrix Metalloproteinase 9